Aug 2026· Clinica chimica acta; international journal of clinical chemistry· pp.
121261
· 0 citations· 99 references
Medicine
TL;DR
Many clinically relevant biomarkers and molecular targets used in cancer research including EGFR, KRAS, BRAF, BCR-ABL1, circulating tumor DNA (ctDNA), and methylated SEPT9 will be examined.
Abstract
A new generation of molecular tests has revolutionized laboratory medicine through allowing for quick, sensitive, and precise identification of the pathogen; genetic mutation or alteration; and disease-related bio-markers. Of all the molecular techniques that exist today, PCR is still the most versatile, and clinically applicable technique available. This paper reviews the development of PCR technology from traditional amplification to advanced platforms including qPCR, dPCR, RT-PCR, and multiplex PCR. Each of the advanced platforms reviewed will be examined for their contributions to both the accurate detection, and quantification of nucleic acids along with the ability to perform high throughput analyses. Additionally, this paper also discusses how PCR technology can be integrated with additional technologies such as NGS, CRISPR-based diagnostic systems, microarrays, and epigenetic profiling to provide a larger view of disease states than was previously possible. Specifically, the focus of this paper will include many clinically relevant biomarkers and molecular targets used in cancer research including EGFR, KRAS, BRAF, BCR-ABL1, circulating tumor DNA (ctDNA), and methylated SEPT9. These biomarkers and molecular targets have greatly enhanced early diagnosis, prognostication, treatment monitoring and precision medicine in cancer research and other areas. The use of PCR-based technologies in diagnosing infectious diseases, tracking AMR, detecting heritable disorders, studying microbial communities, and MRD monitoring were also discussed. Further discussion included current trends in integrating multiple omics data types into a single platform using AI assisted data analysis tools. Liquid biopsy technologies and point-of-care molecular test platforms were also discussed. Although there are continuing challenges related to costs associated with developing these technologies, establishing standardized protocols for each technology type developed, having skilled technicians develop and validate these technologies, and managing large amounts of data generated when using these technologies; continued advances are providing greater access to these technologies to clinicians and ultimately patients.
Background: The diagnosis of infectious diseases currently relies predominantly on polymerase chain reaction (PCR) assays. However, the range of pathogens that can be detected simultaneously using these methods is limited, and their effective use depends on an a priori etiological hypothesis. Multiplex PCR-based target...
M. I. Nadtoka, A. Bukharina, G. Roev et al.· Diagnostics· 0 citations
Various detection methods within LAMP, recent advancements including extraction, multiplexing, and quantification, as well as key clinical applications of LAMP from a syndromic perspective are covered.
Ryan Chaffee, Nabil Royez, J. Burke-Gaffney et al.· Clinical Microbiology Review...· 0 citations
Sarcomas are rare and heterogeneous malignancies for which molecular diagnostics increasingly complement histopathology, immunohistochemistry, FISH, and RT-PCR. This review summarizes the main research applications of next-generation sequencing (NGS) in sarcoma, with particular attention to mutation and variant discove...
A. De Vita, Sara Violani, G. Miserocchi et al.· Current Oncology Reports· 0 citations
Although pre-analytical limitations remain to be fully characterized, integrating CRISPR into the diagnostic workflow may contribute to a rapid, cost-effective, and highly specific framework for the early detection of PDAC.
M. A. Rocco, Milda Kirvaitytė, Giulia Lencioni et al.· Cancer Letters· 0 citations
Some of the recent work on dPCR-based RMPs are described and how this can be applied to improve nucleic acid analysis measurements on a global scale in EQA schemes, clinical laboratories and harmonization studies for infectious disease diagnostics are discussed.
S. Falak, D. O'Sullivan, M. Cleveland et al.· 150th anniversary of the Met...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.